Lupin pulls diabetes drug metformin off shelves as carcinogen worries continue to build

Lupin Pharmaceuticals has pulled all lots of metformin after discovering unacceptably high levels of a probable carcinogen, N-Nitrosodimethylamine (NDMA), in tested samples, the drugmaker said Tuesday.

The recall includes the 500- and 1,000-milligram versions of extended-release metformin sold in 60-, 90- and 100-count bottles distributed between early November and late May, Lupin said.

Read entire article